MarketPR
EARNINGSUS industrial production rises 0.7 percent in SeptemberOct 20EARNINGSOaktree Specialty Lending Sets November 17 Date for Q4 and Full-Year 2026 EarningsOct 20MSMorgan Stanley Lifts Amazon Target to $350, Citing AI-Driven AWS GrowthOct 20ASTCAstrotech approves 1st Detect bonus plan tied to sale proceedsOct 20MDTMedtronic completes MiniMed separation via share exchangeOct 20MACROUS Import and Export Prices Rise on Sticky Inflation ConcernsOct 20STLDSteel Dynamics promotes six executives to support long-term growth strategyOct 20MACROSeptember CPI Jump to 3.7% Pressures Stocks Despite Long-Term GainsOct 20REGULATORYDisney acquires Character.AI assets via bankruptcy restructuringOct 20CRYPTOPlex Media Server flaws under active exploitationOct 20EARNINGSUS industrial production rises 0.7 percent in SeptemberOct 20EARNINGSOaktree Specialty Lending Sets November 17 Date for Q4 and Full-Year 2026 EarningsOct 20MSMorgan Stanley Lifts Amazon Target to $350, Citing AI-Driven AWS GrowthOct 20ASTCAstrotech approves 1st Detect bonus plan tied to sale proceedsOct 20MDTMedtronic completes MiniMed separation via share exchangeOct 20MACROUS Import and Export Prices Rise on Sticky Inflation ConcernsOct 20STLDSteel Dynamics promotes six executives to support long-term growth strategyOct 20MACROSeptember CPI Jump to 3.7% Pressures Stocks Despite Long-Term GainsOct 20REGULATORYDisney acquires Character.AI assets via bankruptcy restructuringOct 20CRYPTOPlex Media Server flaws under active exploitationOct 20
NewsMacro

Pomerantz LLP investigates investor claims against Ionis Pharmaceuticals (IONS)

A securities plaintiff firm has put Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) in focus. Pomerantz LLP disclosed on July 16, 2026, that it is investigating claims on behalf of investors in the NASDAQ-listed company. The firm named Danielle Peyton as the point of contact, reachable at [email protected] or 646-581-9980, ext. 7980.

By Grant HalloranMacro DeskJuly 17, 20262 min read
Share

Key takeaways

  • Pomerantz LLP disclosed on July 16, 2026, that it is investigating claims on behalf of investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS).
  • The disclosure was issued from New York via PRNewswire and is limited to the fact of the investigation plus contact details for affected investors.
  • The firm named Danielle Peyton as the point of contact, reachable at [email protected] or 646-581-9980, ext. 7980.
  • Pomerantz provided no information about what triggered the inquiry, the nature of the claims, or the time period at issue.
  • No formal complaint, class period, or specific allegations have been announced as of the disclosure.

A securities plaintiff firm has put Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) in focus. Pomerantz LLP disclosed on July 16, 2026, that it is investigating claims on behalf of investors in the NASDAQ-listed company. The firm named Danielle Peyton as the point of contact, reachable at [email protected] or 646-581-9980, ext. 7980.

What the disclosure contains

The announcement was issued from New York via PRNewswire on July 16, 2026. Pomerantz identified Ionis Pharmaceuticals by its full legal name and NASDAQ ticker. The firm offered no information about what triggered the inquiry, the nature of the claims, or the time period at issue. The disclosure is limited to the fact of the investigation and contact details for affected investors.

What to watch

The next material development would be a formal complaint, if Pomerantz elects to file one. That document would identify the class period, the allegations, and the legal theory. Nothing of that kind has been announced. For investors who believe they may have a claim, the firm's designated contact is Danielle Peyton at 646-581-9980, ext. 7980, or [email protected].

About this story

Filed by the macro desk of MarketPR on July 17, 2026. Source: prnewswire.com. Indicative figures are not investment advice.

←Back to the news index

More from the Newsroom

All stories →
01Macro

Outstanding margin debt hits $1.5 trillion, a record high

Outstanding margin debt has reached $1.5 trillion, marking a new all-time high. This level of leverage represents the fourth time since 1997 that outstanding margin debt has surged by at least 65% over a short period. The previous three…

Grant Halloran2 min read
02Macro

Berkshire stock hits post-Buffett high as Bending Spoons stake gains

Berkshire Hathaway shares closed Friday at their highest level since Warren Buffett announced in May 2025 that he planned to step down as CEO at the end of that year. Class A shares (BRK.A) ended the session at $798,000, while Class B…

Grant Halloran2 min read
03Macro

Vanguard S&P 500 ETF offers 0.03% expense ratio for $1,000 investment

The Vanguard S&P 500 ETF (VOO) charges an expense ratio of 0.03%, a cost that amounts to $0.30 on a $1,000 investment. The fund, which holds approximately $1.7 trillion in assets, provides exposure to the S&P 500 index, a benchmark…

Grant Halloran2 min read

Frequently asked

Who is investigating Ionis Pharmaceuticals and when was it announced?

Pomerantz LLP disclosed on July 16, 2026, that it is investigating claims on behalf of investors in Ionis Pharmaceuticals (NASDAQ: IONS).

What specific allegations has Pomerantz made against Ionis?

The firm offered no information about what triggered the inquiry, the nature of the claims, or the time period at issue; the disclosure is limited to the fact of the investigation.

How can affected investors contact the firm?

Investors can reach the designated contact, Danielle Peyton, at [email protected] or 646-581-9980, ext. 7980.

Has a lawsuit been filed against Ionis Pharmaceuticals?

No, a formal complaint would be the next material development if Pomerantz elects to file one, but nothing of that kind has been announced.

What would a formal complaint reveal if one is filed?

It would identify the class period, the allegations, and the legal theory.